Loading news...
Callodine Capital Management LP grew its stake in Sanofi (NASDAQ: SNY) by 35.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 698,046 shares of the company's stock after acquiring an additional 182,837 shares during the period. Sanofi accounts for
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)
Brazilian drugmaker EMS is open to fresh acquisitions to expand internationally after inking a major deal to buy Sanofi's Brazil-based generic drugmaker Medley, and is gearing up to launch its own semaglutide-based injector pens in its home market.
Sanofi (NASDAQ: SNY - Get Free Report) shares hit a new 52-week low during mid-day trading on Friday. The company traded as low as $44.01 and last traded at $44.01, with a volume of 93153 shares. The stock had previously closed at $45.00. Analysts Set New Price Targets SNY has been the topic of several
Sanofi is deeply undervalued, trading at a 29% discount to a $65 fair value estimate, with a forward P/E of 9.2 versus a 10-year average of 13. Robust growth is driven by blockbuster drugs like Dupixent and a strong pipeline, supporting consensus EPS growth of 9.3% annually through 2028. SNY offers a 5.1% dividend yield, backed by 31 consecutive annual increases and a sustainable payout ratio in the high-40% range.
Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Document d'Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma giant rights to a blood cancer drug that won Chinese regulatory approval last month.
SNY wins Japan orphan drug tag for Waylirz in IgG4-RD and adds regulatory perks as the BTK inhibitor advances in late-stage studies.
American Century Companies Inc. raised its holdings in shares of Sanofi (NASDAQ: SNY) by 19.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,338,969 shares of the company's stock after purchasing an additional 379,784 shares during the period. American
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Becker Capital Management Inc. cut its holdings in shares of Sanofi (NASDAQ: SNY) by 8.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 522,681 shares of the company's stock after selling 45,719 shares during the quarter. Becker Capital Management
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi's commitment to rare immune-mediated diseases Paris, March 2, 2026 – The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton's tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD). There is still unmet medical need and limited treatment options in Japan for IgG4-RD, a rare, progressive, immune-mediated chronic condition in which the immune system attacks various tissues and organs leading to serious damage.
Citigroup Inc. reduced its holdings in shares of Sanofi (NASDAQ: SNY) by 48.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,253 shares of the company's stock after selling 226,396 shares during the quarter. Citigroup Inc.'s holdings in Sanofi were
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 study demonstrating up to 96 percent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness The therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens and help support the World Health Organization's (WHO) goal of eliminating the disease by 2030 Sanofi will donate the medicine to WHO through its philanthropic arm Foundation S Kinshasa / Paris / Geneva / Amsterdam – February 27, 2026.
• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the US to treat nine distinct diseases driven in part by type 2 inflammation, including sino-nasal, skin, gut and respiratory system diseases that affect a broad range of patients, from infants to elderly adults Paris and Tarrytown, NY, February 24, 2026. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery.
Texas Attorney General Ken Paxton on Thursday sued Sanofi for allegedly "bribing" providers to prescribe its medications over alternatives.